According to the World Health Organization (WHO), cancer is the second leading causes of mortality worldwide. In this context, it is important to highlight that around 10 million cancer deaths are reported globally each year. Further, it is estimated that, by 2030, around 21.4 million new patients are likely to be diagnosed with cancer annually. In fact, the global cancer burden is likely to increase by 70%, over the next two decades. With an aim to counter the rising number of cancer cases across the globe, several pharmaceutical players have developed cell invasion and migration assays to expediate the diagnosis process. It is worth highlighting that early diagnosis of cancer helps the patients to respond to therapy in an effective manner, thereby, increasing the chances of survival. Considering the various advantages offered by these cell-based assays, researchers across the globe have undertaken several initiatives to use these platforms for the diagnosis of a myriad of disease indications. The advancements in various technologies have propelled life science companies to use these assays in the drug discovery process, to enable the identification of potential lead candidates.
Given their extensive utilization in various drug discovery, tumor study and screening applications, there has been a significant rise in the revenue generation potential associated with cell invasion and migration assay kits. The current market landscape is consolidated and primarily dominated by the presence of large players. It is also worth mentioning that over 900 patents related to the implementation of invasion and migration assays have been filed / granted in the past few years, demonstrating the continued innovation in this domain. Taking into consideration both historical and recent developments, it is evident that the cell invasion and migration assay kits market is anticipated to grow at a significant pace in the coming years.
The “Cell Invasion and Migration Assay Market by Type of Assay (Cell Invasion Assay and Cell Migration Assay), Application Areas (Drug Discovery, Screening and Tumor Study), Detection Method Used (Colorimetry and Fluorometry) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022 - 2035” report features an extensive study of the current market landscape and the likely future potential associated with the cell invasion and migration assay market, over the next decade. The study also includes a detailed analysis of key drivers and trends within this evolving market.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Given their extensive utilization in various drug discovery, tumor study and screening applications, there has been a significant rise in the revenue generation potential associated with cell invasion and migration assay kits. The current market landscape is consolidated and primarily dominated by the presence of large players. It is also worth mentioning that over 900 patents related to the implementation of invasion and migration assays have been filed / granted in the past few years, demonstrating the continued innovation in this domain. Taking into consideration both historical and recent developments, it is evident that the cell invasion and migration assay kits market is anticipated to grow at a significant pace in the coming years.
Scope of the Report
The “Cell Invasion and Migration Assay Market by Type of Assay (Cell Invasion Assay and Cell Migration Assay), Application Areas (Drug Discovery, Screening and Tumor Study), Detection Method Used (Colorimetry and Fluorometry) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022 - 2035” report features an extensive study of the current market landscape and the likely future potential associated with the cell invasion and migration assay market, over the next decade. The study also includes a detailed analysis of key drivers and trends within this evolving market.
Amongst other elements, the report features:
- A detailed overview of the current market landscape of companies engaged in offering cell invasion and migration assays based on several parameters, such as year of establishment, company size, location of headquarters, type of end-user (industry and non-industry).
- A detailed overview of the overall market landscape of cell invasion and migration assays, based on several relevant parameters, such as type of cell culture (adherent and suspension cell culture), type of assay (cell invasion and cell migration assay), number of wells (24-well, 32-well, 48-well, 96-well and 384-well), pore size of wells (3 µm, 5 µm , 8 µm , 9 µm and 12 µm), type of ECM coating (basement membrane extract, collagen I, collagen IV, fibronectin and laminin), storage temperature (ultra-low, frozen, refrigerated and room temperature), application area (drug discovery, screening and tumor study), detection method used (colorimetry and fluorometry) and number of assays performed.
- An insightful product competitiveness analysis of cell invasion and migration assays, based on their supplier strength (in terms of years of experience and company size) and product portfolio strength (which takes into account type of cell culture, number of wells, type of ECM coating, kit components, application area, detection method used and number of assays performed).
- Elaborate profiles of cell-based assay providers (large and mid-sized companies, established before 2000). Each profile features a brief overview of the company, along with information on its product portfolio, recent developments and an informed future outlook.
- A detailed review of around 675 peer-reviewed, scientific articles related to research on cell invasion and migration assays, based on several relevant parameters, such as year of publication, type of publication, popular keywords, top journals, top institutes and top authors (in terms of number of articles published).
- An in-depth analysis of patents related to cell invasion and migration assays filed / granted since 2017, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (in terms of number of patents filed / granted). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
- A detailed review of academic grants that have been awarded to various research institutes for projects focused on cell invasion and migration, during the period, 2017-2022, based on several parameters, such as year of grant award, amount awarded, support period, type of funding institute center, support period, grant application, purpose of grant award, grant activity code, NIH spending category, study section involved, popular NIH departments, recipient organization, regional distribution of recipient organization. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.
- A Bowman’s strategy clock framework to understand the pricing strategy of the cell invasion and migration assays offered by a company, along with its competitive position. In addition, it presents the equation devised to calculate the likely price of the cell invasion and migration assays based upon its characteristics.
- One of the key objectives of the report was to estimate the existing market size and estimate the future size of cell invasion and migration assays market. We have provided informed estimates on the evolution of the market, over the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of assay (cell invasion assay and cell migration assay), [B] application area (drug discovery, screening and tumor study), [C] detection method used (colorimetry and fluorometry) and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Which companies are engaged in offering cell invasion and migration assays kits?
- What is the most common assay format (in terms of number of wells) offered by cell invasion and migration assay providers?
- What are the key geographical regions where cell invasion and migration assay providers are located?
- What is the evolving trend of publications focused on cell invasion and migration assays?
- Which companies are actively filing patents to drive innovation in the field of cell invasion and migration assays?
- What are the key factors influencing the price of cell invasion and migration assays?
- What are the key challenges associated with cell invasion and migration assays?
- How is the current and future market opportunity likely to be distributed across key market segments?
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. PRODUCT COMPETITIVENESS ANALYSIS
6. COMPANY PROFILES
7. PUBLICATION ANALYSIS
8. PATENT ANALYSIS
9. GRANT ANALYSIS
10. BOWMAN CLOCK PRICING STRATEGY
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12. CONCLUSION
List Of Figures
List Of Tables
Companies Mentioned
- Abcam
- Acomhal Research
- Alabama State University
- Albert Einstein College of Medicine
- Assay Genie
- Baltimore VA Medical Center
- Baylor College of Medicine
- Beckman Research Institute
- BioVision
- Boston University
- Brigham and Women's Hospital
- Brown University
- California Institute of Technology
- California State Polytechnic University
- Carnegie Mellon University
- Case Western Reserve University
- Cedars-Sinai Medical Center
- Cell Biolabs
- Cell Reprogramming & Therapeutics
- Cincinnati Children's Hospital Medical Center
- Cleveland Clinic Lerner College of Medicine
- Columbia University Health Sciences
- Cornell University
- Dana-Farber Cancer Institute
- Drexel University
- Duke University
- Echelon Biosciences
- Emory University
- Endomet Biosciences
- Enzo Life Sciences
- Fesarius Therapeutics
- Florida International University
- Florida State University
- Fox Chase Cancer Center
- Fred Hutchinson Cancer Research Center
- Georgetown University
- H. Lee Moffitt Cancer Center & Research Institute
- Icahn School of Medicine
- Indiana University–Purdue University Indianapolis
- Iowa State University
- Johns Hopkins University
- LifeSpan BioSciences
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Mayo Clinic
- Memorial Sloan Kettering Cancer Center
- MilliporeSigma
- Morehouse School of Medicine
- MyBioSource
- National Cancer Institute
- New Mexico State University
- New York University
- North Carolina Agricultural and Technical State University
- NYU Grossman School of Medicine
- Ohio State University
- Oregon Health & Science University
- Penn State Health Milton S. Hershey Medical Center
- Planet Biotechnology
- Platypus Technologies
- Ponce Health Sciences University
- R&D Systems
- Ralph H. Johnson VA Medical Center
- Rockefeller University
- Roswell Park Comprehensive Cancer Center
- Rowan University
- Rutgers Biomedical and Health Sciences
- Salk Institute for Biological Studies
- Sanford Burnham Prebys
- Sapphire Biotech
- Sigma-Aldrich
- St. Joseph's Hospital and Medical Center
- Stanford University
- Stony Brook University
- Stowers Institute for Medical Research
- Syntrix Biosystems
- Temple University
- Texas A&M University
- The Catholic University of America
- The University of Texas
- The University of Texas Health Science Center
- The University of Texas MD Anderson Cancer Center
- Tufts University
- Tuskegee University
- Universidad Central Del Caribe
- University of Alabama
- University of Arizona
- University of Arkansas
- University of California
- University of Chicago
- University of Colorado Denver
- University of Connecticut
- University of Delaware
- University of Florida
- University of Houston
- University of Illinois
- University of Kentucky
- University of Louisville
- University of Maryland
- University of Miami
- University of Michigan
- University of Minnesota
- University of Nevada
- University of North Carolina
- University of Oklahoma Health Sciences Center
- University of Pennsylvania
- University of Pittsburgh
- University of Puerto Rico
- University of South Dakota
- University of Southern California
- University of Toledo
- University of Utah
- University of Vermont College of Agriculture and Life Sciences
- University of Virginia
- University of Washington
- University of Wisconsin-Madison
- Upstate Medical University
- Utah State University
- VA Eastern Colorado Health Care System
- Vanderbilt University
- Vanderbilt University Medical Center
- Veterans Health Administration
- Washington University
- Weill Medical College of Cornell University
- West Virginia University
- Whitehead Institute
- Wistar Institute
- Wright State University
- Yale University
Methodology
LOADING...
![Multiplex Assays Market by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Cardiovascular, Infectious, Autoimmune Diseases) Product, End User - Global Forecast to 2030 - Product Image](http://www.researchandmarkets.com/product_images/12541/12541970_60px_jpg/multiplex_assays_market.jpg)
